河南羚锐制药股份有限公司关于“提质增效重回报”行动方案的公告

Core Viewpoint - The company has developed an action plan titled "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" to enhance operational quality and competitiveness, aligning with government initiatives and market expectations [1] Group 1: Strategic Focus - The company aims to strengthen its core pharmaceutical business, particularly in orthopedics and cardiovascular fields, while enhancing brand and product category development [2] - Future strategies include optimizing business structure, improving operational efficiency, and advancing product innovation, particularly in transdermal patches [2] - The company plans to upgrade manufacturing capabilities through technological innovations and expand its distribution channels to create a comprehensive national network [2] Group 2: Innovation-Driven Development - The company adheres to an "innovation-driven development" strategy, focusing on product innovation as a key growth engine [3] - It will leverage its research platforms to enhance capabilities in traditional Chinese medicine and advanced formulations, particularly in pain management and chronic disease areas [3] - Increased investment in research and development will target quality control, process improvement, and clinical value exploration [3] Group 3: Governance and Compliance - The company is committed to enhancing its governance structure in accordance with relevant laws and regulations, ensuring the protection of shareholder rights [4] - Plans include strengthening the roles of various board committees and enhancing the decision-making process through independent directors [5] Group 4: Shareholder Return Mechanism - The company emphasizes investor returns, having distributed a total of RMB 2.544 billion in cash dividends since its listing in 2000 [6] - A three-year shareholder return plan (2024-2026) will be established to ensure stable and predictable returns based on operational performance and shareholder expectations [6] Group 5: Investor Relations and Information Disclosure - The company will enhance its information disclosure practices to ensure transparency and timely communication with investors [7] - Efforts will be made to improve investor relations management and actively engage with core investor groups [7] Group 6: Responsibility System for Key Personnel - The company focuses on the management of key personnel, ensuring compliance and enhancing their responsibilities through training and performance evaluation [8] - A robust responsibility system will be established to strengthen compliance awareness and operational effectiveness among key stakeholders [8]